This is a knockout-validated antibody summary, based on the publication "MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Company: Cell Signaling

Antibody: Mnk1

Catalog number: 2195S

Summary: Rabbit monoclonal IgG against a synthetic peptide corresponding to the sequence of human Mnk1. Rects with human and mouse by western blot.

Western blot | Immunohistochemistry

Control and MNK1 knock-out MCF10DCIS.com cells and xenografts. WB: Cells were lysed with RIPAbuffer (150 mmol/LTris-HCl, pH 7, 150 mmol/L NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) supplemented with protease and phosphatase inhibitors (Roche) as described previously.

IHC: Slides were scanned and assessed using Spectrum (Aperio Technologies).

MNK1 knock-out by CRISPR-Cas 9 technology in 2 independent clones is confirmed by WB. MNK1 knockout is retained in the DCIS-Luc MNK1-KO xenografts as confirmed by IHC. Scale bar, 50 μm. Please see Supplementary Figure 2a and Figure 2b in the article [1].